CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 190 filers reported holding CATALYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $288,649 | +9.3% | 24,692 | +25.7% | 0.00% | 0.0% |
Q2 2023 | $264,069 | -18.9% | 19,648 | 0.0% | 0.00% | -50.0% |
Q1 2023 | $325,764 | +15.1% | 19,648 | +29.1% | 0.00% | 0.0% |
Q4 2022 | $283,148 | +137.9% | 15,223 | +64.8% | 0.00% | +100.0% |
Q3 2022 | $119,000 | +83.1% | 9,240 | 0.0% | 0.00% | – |
Q2 2022 | $65,000 | -52.6% | 9,240 | -44.1% | 0.00% | -100.0% |
Q1 2022 | $137,000 | +144.6% | 16,535 | +99.8% | 0.00% | – |
Q4 2021 | $56,000 | +51.4% | 8,277 | +19.9% | 0.00% | – |
Q3 2021 | $37,000 | -7.5% | 6,904 | 0.0% | 0.00% | – |
Q2 2021 | $40,000 | +25.0% | 6,904 | 0.0% | 0.00% | – |
Q1 2021 | $32,000 | +39.1% | 6,904 | 0.0% | 0.00% | – |
Q4 2020 | $23,000 | +9.5% | 6,904 | 0.0% | 0.00% | – |
Q3 2020 | $21,000 | -34.4% | 6,904 | 0.0% | 0.00% | – |
Q2 2020 | $32,000 | +18.5% | 6,904 | 0.0% | 0.00% | – |
Q1 2020 | $27,000 | +3.8% | 6,904 | 0.0% | 0.00% | – |
Q4 2019 | $26,000 | -29.7% | 6,904 | 0.0% | 0.00% | – |
Q3 2019 | $37,000 | +54.2% | 6,904 | +9.4% | 0.00% | – |
Q2 2019 | $24,000 | – | 6,309 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANAKA CAPITAL MANAGEMENT INC | 589,883 | $590,000 | 1.38% |
Broadfin Capital, LLC | 8,200,000 | $8,610,000 | 0.96% |
Avoro Capital Advisors LLC | 1,141,149 | $1,198,000 | 0.24% |
CORRADO ADVISORS, LLC | 190,600 | $200,000 | 0.12% |
Baker Brothers Advisors | 5,102,153 | $5,357,000 | 0.05% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 756,311 | $794,000 | 0.04% |
Point72 Asset Management, L.P. | 2,272,816 | $2,386,000 | 0.02% |
AGRAN LIBBIE | 44,000 | $46,000 | 0.01% |
COMPTON CAPITAL MANAGEMENT INC /RI | 10,000 | $11,000 | 0.01% |
KENNEDY CAPITAL MANAGEMENT LLC | 233,171 | $245,000 | 0.00% |